L.A. Mckeown

The curves for TVF separated early and remained parallel in the complex cases, giving an advantage to the DCB group at 1 year.

Durability questions remain, but Myval appears comparable to contemporary devices on the market, says Patrick Serruys.

This month: questionable value of management consultants, BP across the lifespan, patient frailty perspectives in HF, and more.

The results support the potential to change the trajectory of kidney function decline and extend life expectancy.

While operators from different camps have disparate views and expectations, most agree the time is right for a definitive trial.

Race and ethnicity modified the associations, with the hypotension connection considered to be hypothesis-generating.

Compared with nonusers, those on a GLP-1 receptor agonist had fewer thromboembolic events and higher survival.

The proposed decision memo also paves the way for triaging by chart review and enhancing flexibility for heart team decisions.

The combination of consistent strength training, aerobic activity, and limited sedentary time yielded the greatest benefits.

This month: Medically tailored meals, nurses front and center for prevention, GLP-1s and muscle mass in cardiac rehab, and more.